A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate

PHASE2CompletedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

October 20, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

September 17, 2019

Conditions
Rheumatoid Arthritis
Interventions
DRUG

E6011

subcutaneous administration

DRUG

Placebo

subcutaneous administration

Trial Locations (90)

Unknown

Eisai Trial Site #1, Nagoya

Eisai Trial Site #2, Nagoya

Eisai Trial Site #3, Nagoya

Eisai Trial Site #4, Nagoya

Eisai Trial Site #1, Toyohashi

Eisai Trial Site #1, Toyota

Eisai Trial Site #1, Funabashi

Eisai Trial Site #1, Matsuyama

Eisai Trial Site #1, Iizuka

Eisai Trial Site #1, Kitakyushu

Eisai Trial Site #1, Kurume

Eisai Trial Site #2, Kurume

Eisai Trial Site #1, Takasaki

Eisai Trial Site #2, Takasaki

Eisai Trial Site #1, Asahikawa

Eisai Trial Site #1, Hakodate

Eisai Trial Site #1, Kushiro

Eisai Trial Site #1, Sapporo

Eisai Trial Site #2, Sapporo

Eisai Trial Site #3, Sapporo

Eisai Trial Site #1, Tomakomai

Eisai Trial Site #1, Kobe

Eisai Trial Site #1, Takarazuka

Eisai Trial Site #1, Hitachi

Eisai Trial Site #1, Hitachi-Naka

Eisai Trial Site #1, Kasama

Eisai Trial Site #1, Komatsu

Eisai Trial Site #1, Morioka

Eisai Trial Site #1, Kirishima

Eisai Trial Site #1, Yokohama

Eisai Trial Site #2, Yokohama

Eisai Trial Site #1, Yamaga

Eisai Trial Site #1, Yokkaichi

Eisai Trial Site #1, Ōsaki

Eisai Trial Site #1, Sendai

Eisai Trial Site #2, Sendai

Eisai Trial Site #1, Hyūga

Eisai Trial site #2, Hyūga

Eisai Trial Site #1, Matsumoto

Eisai Trial Site #1, Isahaya

Eisai Trial Site #1, Ōmura

Eisai Trial Site #1, Sasebo

Eisai Trial Site #1, Nagaoka

Eisai Trial Site #1, Shibata

Eisai Trial Site #1, Beppu

Eisai Trial Site #1, Tomigusuku

Eisai Trial Site #1, Kawachi-Nagano

Eisai Trial Site #1, Ureshino

Eisai Trial Site #1, Hiki

Eisai Trial Site #1, Kawagoe

Eisai Trial Site #1, Kawaguchi

Eisai Trial Site #1, Tokorozawa

Eisai Trial Site #1, Hamamatsu

Eisai Trial Site #1, Shimotsuke

Eisai Trial Site #1, Bunkyo

Eisai Trial Site #1, Chūō

Eisai Trial Site #1, Fuchū

Eisai Trial Site #1, Meguro City

Eisai Trial Site #1, Musashino

Eisai Trial Site #1, Nakano City

Eisai Trial Site #1, Ōme

Eisai Trial Site #1, Ōta-ku

Eisai Trial Site #1, Setagaya City

Eisai Trial Site #1, Shinjuku

Eisai Trial Site #2, Shinjuku

Eisai Trial Site #1, tabashi City

Eisai Trial Site #1, Takaoka

Eisai Trial Site #1, Nishimuro

Eisai Trial Site #1, Shimonoseki

Eisai Trial Site #2, Shimonoseki

Eisai Trial Site #1, Fukui

Eisai Trial Site #2, Fukuoka

Eisai Trial Site #1, Gifu

Eisai Trial Site #1, Hiroshima

Eisai Trial Site #2, Hiroshima

Eisai Trial Site #3, Hiroshima

Eisai Trial Site #1, Kagoshima

Eisai Trial Site #2, Kagoshima

Eisai Trial Site #3, Kagoshima

Eisai Trial Site #1, Kochi

Eisai Trial Site #2, Kumamoto

Eisai Trial Site #1, Miyagi

Eisai Trial Site #1, Miyazaki

Eisai Trial Site #1, Nagano

Eisai Trial Site #1, Nagasaki

Eisai Trial Site #2, Nagasaki

Eisai Trial Site #3, Nagasaki

Eisai Trial Site #1, Ōita

Eisai Trial Site #1, Saitama

Eisai Trial Site #1, Shizuoka

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT02960438 - A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate | Biotech Hunter | Biotech Hunter